In the 2009 AACE/ACE consensus algorithm for the treatment of type 2 diabetes, ExBID was suggested as asecondary agent in combination with metformin for dualand triple therapy based on the overall clinical profile ofexenatide (5). Exenatide was also cited as a potentialadd-on therapy in the 2009 American Diabetes Associa-tion/European Association for the Study of Diabetes al-gorithm (4). Although ExBID has a greater effect on post-prandial glucose concentrations compared with ExQW(16), the once-weekly formulation still produces greaterreductions in HbA1c and fasting hyperglycemia comparedwith ExBID, with a lower risk of gastrointestinal adverseevents. These three benefits demonstrate the value ofExQW within the class of GLP-1 receptor agonists. It should be noted that dipeptidyl-peptidase-4 inhibitors